Anti-Cancer

Imatinib (GLIVEC) Tablet

Name: Imatinib (GLIVEC) Tablet
Brand: variable
Availability: InStock

$79.00

Imatinib Glivec 100/400 MG Tablet represents a monumental therapeutic breakthrough in the management of chronic myeloid leukemia, gastrointestinal stromal tumors, and other cancers, offering targeted therapy that can significantly improve outcomes and quality of life for patients facing these challenging conditions.

Sku:

N/A

Tag:

Imatinib GLIVEC

Description

Imatinib Glivec 100/400 MG Tablet stands as a cornerstone medication in the field of oncology, offering a transformative treatment option for individuals battling chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and certain other rare cancers. With its active ingredient imatinib mesylate, this oral medication represents a monumental advancement in the management of these complex conditions, providing renewed hope and significantly improved outcomes for patients facing these challenging diagnoses.

Key Features:

Targeted Therapy: Imatinib is a tyrosine kinase inhibitor (TKI) that selectively targets and inhibits the activity of BCR-ABL fusion protein, c-KIT, and platelet-derived growth factor receptor (PDGFR), among other tyrosine kinases implicated in the pathogenesis of CML, GIST, and other cancers. By disrupting these signaling pathways, imatinib effectively suppresses the proliferation and survival of cancer cells, leading to disease control and improved survival rates.
Treatment of Chronic Myeloid Leukemia (CML): Imatinib Glivec Tablet is indicated for the treatment of newly diagnosed and recurrent or refractory CML in adults and pediatric patients. It represents the first-line therapy for CML, offering durable responses and long-term disease control in the majority of patients.
Treatment of Gastrointestinal Stromal Tumors (GIST): Imatinib is also approved for the treatment of unresectable or metastatic GIST, where it has demonstrated remarkable efficacy in inducing tumor regression, prolonging progression-free survival, and improving overall survival rates. It serves as a standard-of-care therapy for patients with GIST, particularly those with mutations in the c-KIT receptor.
Oral Administration: Administered orally once daily, Imatinib Glivec Tablet is typically taken with a meal and a large glass of water to minimize gastrointestinal side effects. Patients should adhere strictly to the prescribed dosing schedule and follow healthcare provider instructions meticulously.
Multiple Strengths: Available in tablet form with strengths of 100mg and 400mg, Imatinib Glivec Tablet allows for personalized dosing tailored to individual patient needs and treatment responses, facilitating optimized therapeutic outcomes.
Efficacy: Clinical trials have demonstrated the remarkable efficacy of imatinib in inducing hematologic and cytogenetic responses in patients with CML, as well as durable responses and disease control in patients with GIST and other cancers. It has shown superiority over conventional chemotherapy and other treatment modalities, both as a frontline therapy and in patients with resistant or refractory disease.
Side Effects: Common side effects of Imatinib may include nausea, diarrhea, fluid retention, muscle cramps, and fatigue. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.
Patient Education: Patients should receive comprehensive counseling on proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated on the need for regular monitoring of blood counts and other parameters to assess treatment response and detect any adverse effects.
Consultation with Healthcare Provider: Treatment with Imatinib Glivec Tablet should be initiated and monitored by a qualified hematologist or oncologist experienced in the management of CML, GIST, and other cancers. Close collaboration between the patient and healthcare provider is essential throughout the treatment journey.

Access and Affordability: Efforts should be made to ensure access to Imatinib for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate the financial burden of treatment.

In conclusion, Imatinib Glivec 100/400 MG Tablet represents a monumental therapeutic breakthrough in the management of chronic myeloid leukemia, gastrointestinal stromal tumors, and other cancers, offering targeted therapy that can significantly improve outcomes and quality of life for patients facing these challenging conditions. With careful monitoring, patient education, and access to treatment, Imatinib holds promise in reshaping the landscape of oncology and providing hope for those affected by these diseases.